Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia
| Autor: | Oliver Bolte, Christian Koenecke, Peter Gielow, Bernd Hertenstein, Elke Dammann, Wolfram H. Knapp, A. R. Boerner, Michael Stadler, Anke Franzke, Arnold Ganser, Michael Hofmann, Matthias Eder |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Cyclophosphamide medicine.medical_treatment Graft vs Host Disease Gastroenterology Antibodies Median follow-up Antigens CD Recurrence Risk Factors Internal medicine medicine Humans Transplantation Homologous Radioisotopes Dose-Response Relationship Drug business.industry Myeloid leukemia Hematology Middle Aged Radioimmunotherapy Surgery Transplantation Survival Rate Regimen Leukemia Myeloid Acute Rhenium Female Stem cell business Cell Adhesion Molecules Busulfan medicine.drug Stem Cell Transplantation |
| Zdroj: | International journal of hematology. 87(4) |
| ISSN: | 0925-5710 |
| Popis: | Between July 2000 and June 2003 a total of 21 patients with high-risk acute myeloid leukemia (AML; n = 14), AML after myelodysplastic syndrome (MDS; n = 6) or advanced MDS (n = 1) were treated with an 188-Re labelled anti-CD66 antibody in the conditioning regimen for allogeneic stem cell transplantation. Radioimmunotherapy (RIT) was followed by standard full-dose conditioning with busulfan and high-dose cyclophosphamide in 11 patients and reduced intensity conditioning regimen in 10 patients. All patients received an unmanipulated allogeneic graft from alternative donors (n = 15) or a HLA-identical familiy donor (n = 6). With a median follow up of 42 months (23–60) disease free survival for all patients was 43%. Nine patients are still alive and in ongoing complete hematological remission. The treatment related mortality was 28.6% (n = 6) and an equal number of patients died of relapsing disease within 30–385 days after transplantation. Late organ toxicity, monitored for more than 1 year, was mild and not clinically relevant. The combination of RIT with chemotherapeutic conditioning seems to be a therapy with an acceptable risk of treatment related morbidity and mortality as well as occurrence of severe acute GvHD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink